| 000 | 01532 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250515044608.0 | ||
| 264 | 0 | _c20061122 | |
| 008 | 200611s 0 0 eng d | ||
| 022 | _a1873-4286 | ||
| 024 | 7 |
_a10.2174/138161206778559786 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGoertsches, Robert | |
| 245 | 0 | 0 |
_aMultiple sclerosis therapy monitoring based on gene expression. _h[electronic resource] |
| 260 |
_bCurrent pharmaceutical design _c2006 |
||
| 300 |
_a3761-79 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aBiomarkers _xmetabolism |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 |
_aCytokines _xgenetics |
| 650 | 0 | 4 |
_aDrug Monitoring _xmethods |
| 650 | 0 | 4 | _aGene Expression Profiling |
| 650 | 0 | 4 |
_aGene Expression Regulation _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunologic Factors _xpharmacology |
| 650 | 0 | 4 |
_aInterferon-beta _xpharmacology |
| 650 | 0 | 4 |
_aLeukocytes, Mononuclear _xdrug effects |
| 650 | 0 | 4 |
_aMultiple Sclerosis _xdrug therapy |
| 650 | 0 | 4 | _aOligonucleotide Array Sequence Analysis |
| 650 | 0 | 4 | _aPatient Selection |
| 650 | 0 | 4 | _aPharmacogenetics |
| 650 | 0 | 4 |
_aRNA, Messenger _xmetabolism |
| 650 | 0 | 4 | _aTime Factors |
| 700 | 1 | _aSerrano-Fernández, Pablo | |
| 700 | 1 | _aMöller, Steffen | |
| 700 | 1 | _aKoczan, Dirk | |
| 700 | 1 | _aZettl, Uwe K | |
| 773 | 0 |
_tCurrent pharmaceutical design _gvol. 12 _gno. 29 _gp. 3761-79 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2174/138161206778559786 _zAvailable from publisher's website |
| 999 |
_c16647952 _d16647952 |
||